Evaluation of effect of bevacizumab on central subfield macular thickness in the injected and contralateral (untreated) eye of patients with bilateral diabetic macular oedema

PURPOSE: Antivascular endothelial growth factor (anti-VEGFs)—bevacizumab is routinely utilised for the treatment of diabetic macular oedema (DME). We plan to evaluate the impact of bevacizumab on the central subfield macular thickness (CSMT) of the treated and untreated eye. METHODS: A sequential gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatri, Anadi, Karki, Pratap, Joshi, Sagun Narayan, Kharel Sitaula, Ranju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895978/
https://www.ncbi.nlm.nih.gov/pubmed/29657972
http://dx.doi.org/10.1136/bmjophth-2017-000102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895978/
https://www.ncbi.nlm.nih.gov/pubmed/29657972
http://dx.doi.org/10.1136/bmjophth-2017-000102

Ejemplares similares